Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
British Journal of Cancer|August 17, 2016
Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profilingLauren C J Baker, Jessica K R Boult, Markus Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH studyAleix Prat, Giampaolo Bianchini, Marlene Thomas, et al.
Cancer Immunology Research|August 9, 2015
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory ReceptorsDaniela S Thommen, Jens Schreiner, Philipp Müller, et al.
Blood Advances|December 23, 2021
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphomaAnn-Marie E Bröske, Koorosh Korfi, Anton Belousov, et al.
Oncoimmunology|April 9, 2016
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptorJens Schreiner, Daniela S Thommen, Petra Herzig, et al.
Science Translational Medicine|March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapyMaud Mayoux, Andreas Roller, Vesna Pulko, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 24, 2020
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and ParkinsonismAhmed Al-Qassabi, Tsu-Shuen Tsao, Adriana Racolta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2021
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I TrialMartin Hutchings, Franck Morschhauser, Gloria Iacoboni, et al.
American Journal of Respiratory and Critical Care Medicine|August 17, 2013
Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary diseaseDonavan T Cheng, Deog Kyeom Kim, Debra A Cockayne, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
Pageof 2